Cidara Therapeutics is reducing its workforce by 30% (20 employees) to focus on the clinical development of its influenza product candidate CD388, expecting to incur about $1.2 million in severance costs. The company plans to start a Phase 2b clinical trial for CD388 in Q3 2024 and will not pursue other product candidates.